[Molecular targeted treatment of hematological diseases with monoclonal antibodies and tyrosine kinase inhibitors. The Danish Society of Hematology].
Explore the source record for details and available documents.
SEARCH · PubMed Health
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The insurance of one's life and one's capacity to work is only exceptionally possible for patients suffering from haematological diseases. Most of these diseases are still fatal after a predictable and thus a short period, in spite of certain therapeutical results. Exceptions such as the healing of, for instance, a lymphatic leucocythaemia are mentioned. It will be dealt with the approximate frequency of the disease, its characteristics and its prognosis.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.